LUNG CANCER

Combination therapy of osimertinib and datopotamab deruxtecan shows promising efficacy in advanced NSCLC, warranting further phase 3 studies.

Taletrectinib emerges as a groundbreaking treatment for ROS1-mutant NSCLC, offering hope with its CNS activity and lower neurological side effects.

Taletrectinib gains FDA approval as a groundbreaking treatment for ROS1-positive non-small cell lung cancer, offering hope for patients with CNS involvement.

Oncologists share their treatment preferences for patients with advanced NSCLC with EGFR mutations.

A recent study reveals promising outcomes for lung cancer patients who undergo rechallenge with different RET inhibitors after initial treatment failure.

A novel combination therapy shows promise for advanced lung cancer patients resistant to standard treatments, offering hope for improved survival rates.

Neoadjuvant nivolumab plus chemotherapy significantly improves overall survival in resectable non-small cell lung cancer, marking a treatment breakthrough.

Benmelstobart alone or with anlotinib improved progression-free survival after chemoradiotherapy in unresectable stage III non–small cell lung cancer.

A molecular test identified patients with high-risk early lung cancer who significantly benefitted from adjuvant chemotherapy, improving survival without disease progression.

Nicolas Girard, MD, PhD, discussed findings from the MARIPOSA and COCOON trials of amivantamab and lazertinib in EGFR+ NSCLC.

First-line cemiplimab showed improved survival vs chemotherapy in advanced NSCLC with brain metastases and PD-L1 ≥50% in EMPOWER-Lung 1.

For patients with EGFR-mutated NSCLC, treatment options in the frontline include osimertinib monotherapy, amivantamab with lazertinib, and osimertinib combined with platinum-doublet chemotherapy.

During a live event, Xiuning Le, MD, PhD, discussed clinical trials of supportive care for infusion reaction and skin rash with amivantamab in EGFR-mutated lung cancer.

Belrestotug plus dostarlimab showed no progression-free survival benefit in NSCLC, leading GSK and iTeos to discontinue all development and ongoing trials.

The FDA granted accelerated approval to telisotuzumab vedotin for the treatment of NSCLC with high c-MET protein overexpression.

Telisotuzumab vedotin plus osimertinib demonstrated safety and efficacy in patients with c-MET protein overexpression.

A post hoc analysis shows significantly improved ORR and PFS in advanced NSCLC with higher AFM24 exposure, supporting optimized dosing strategies.

Phase 1 trial of TGW101 in advanced solid tumors is enrolling to assess safety and pharmacokinetics and define the maximum tolerated dose in up to 50 patients.

Ivonescimab plus chemotherapy improved survival in advanced squamous NSCLC vs tislelizumab and chemotherapy in a phase 3 trial.

Natasha Leighl, MD, MMSc, BSc, discussed key findings from the PALOMA-3 trial for a community oncologist audience.

Jared Weiss, MD, discussed the mechanism of action of JNJ-1900 and the preliminary data presented at the 2025 European Lung Cancer Congress.

The phase 2 SAVANNAH trial of savolitinib plus osimertinib has demonstrated the combination’s efficacy and safety in EGFR-mutated NSCLC.

Subcutaneous pembrolizumab demonstrated comparable efficacy vs intravenous administration in non–small cell lung cancer, with a significantly shorter injection time.

Amit Gupta, MD, discussed a new collaboration between University Hospitals Cleveland Medical Center and Qure.ai that aims to enhance early lung cancer detection.

Final phase 2a results showed that CAN-2409 led to a median overall survival of 24.5 months in immune checkpoint inhibitor–refractory patients with NSCLC.

Shirish M. Gadgeel, MD, discussed long-term data from the MARIPOSA trial of lazertinib and amivantamab in EGFR-mutated non–small cell lung cancer.

During a live event, Alexander I. Spira, MD, PhD, and participants discuss efficacy, adverse events, and sequencing of EGFR-mutated NSCLC treatments.